74 a-TIGIT mAb belrestotug in combination with anti-PD1 induces an immunocompetent tumor microenvironment (TME)

• Maurizio Ceppi,
• Gregory Driessens,
• Bart Claes,
• Stephanie Ma,
• Olivier De Henau,
• Julia Cuende,
• Iain Welsby,
• Nicolas Rosewick,
• Noemie Wald,
• Anais Vezzu,
• Marjorie Mercier,
• Paola Tieppo,
• Yvonne McGrath,
• Marion Libouban

Affiliations

Maurizio Ceppi

3Roche Innovation Center Basel, Basel, Switzerland

Gregory Driessens

Aff1 iTeos Therapeutics Gosselies Belgium

Bart Claes

Vesalius Research Center, VIB, Katholieke Universiteit Leuven, Belgium

Stephanie Ma

2A4P, Kent, UK, UK

Olivier De Henau

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Julia Cuende

1iTeos Therapeutics, Gosselies, BE, Belgium

Iain Welsby

1iTeos Therapeutics, Gosselies, BE, Belgium

Nicolas Rosewick

1iTeos Therapeutics, Gosselies, BE, Belgium

Noemie Wald

1iTeos Therapeutics, Gosselies, BE, Belgium

Anais Vezzu

1iTeos Therapeutics, Gosselies, BE, Belgium

Marjorie Mercier

1iTeos Therapeutics, Gosselies, BE, Belgium

Paola Tieppo

1iTeos Therapeutics, Gosselies, BE, Belgium

Yvonne McGrath

1iTeos Therapeutics, Gosselies, BE, Belgium

Marion Libouban

1iTeos Therapeutics, Gosselies, BE, Belgium